(Q44494414)

3 December 2017

Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis (English)

1 reference

3 December 2017

0 references

0 references

Anahi Fernandez Cuppari

1

1 reference

3 December 2017

Vanesa Sanchez

2

1 reference

3 December 2017

Bibiana Ledesma

3

1 reference

3 December 2017

Fernanda M Frank

4

1 reference

3 December 2017

Alejandra Goldman

5

1 reference

3 December 2017

Sergio O Angel

6

1 reference

3 December 2017

Valentina Martin

7

1 reference

3 December 2017

language of work or name

English

0 references

publication date

21 August 2008

1 reference

3 December 2017

1 reference

3 December 2017

26

1 reference

3 December 2017

39

1 reference

3 December 2017

5040-5045

1 reference

Toxoplasma gondii: from animals to humans

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Toxoplasmic encephalitis in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Immunity to Toxoplasma gondii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Biology of Toxoplasma gondii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Disease burden of congenital toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

A commercial vaccine for ovine toxoplasmosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Molecular cloning, sequencing and expression of a serine proteinase inhibitor gene from Toxoplasma gondii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Subcellular localization and post-secretory targeting of TgPI, a serine proteinase inhibitor from Toxoplasma gondii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Functional analysis of Toxoplasma gondii protease inhibitor 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Influence of genes within the MHC on mortality and brain cyst development in mice infected with Toxoplasma gondii: kinetics of immune regulation in BALB H-2 congenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Population biology of Toxoplasma gondii and its relevance to human infection: do different strains cause different disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

What are the respective host and parasite contributions to toxoplasmosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Interleukin-10 anti-inflammatory response to Borrelia burgdorferi, the agent of Lyme disease: a possible role for suppressors of cytokine signaling 1 and 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Elicitation of specific, Th1-biased immune response precludes skeletal muscle damage in cruzipain-vaccinated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Induction of protective immunity by DNA vaccination with Toxoplasma gondii HSP70, HSP30 and SAG1 genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Toxoplasma gondii: evaluation of an intranasal vaccine using recombinant proteins against brain cyst formation in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

Susceptibility to chronic infection with Toxoplasma gondii does not correlate with susceptibility to acute infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.031

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.07.031

1 reference

3 December 2017

1 reference